Screener
Arcus Biosciences RCUS Other collaboration — Total revenues
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Arcus Biosciences in its filing.
Tagged under the XBRL concept us-gaap:Revenues.
The source filing: Arcus Biosciences’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 4:11 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001724521-26-000044
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Revenues: | ||||
| License and development services (Includes $8, $152, $18 and $172 from a related party) | $16 | $152 | $28 | $172 |
| Other collaboration(Includes $25, $8, $30 and $16 from a related party) | 25 | 8 | 30 | 16 |
| Total revenues | 41 | 160 | 58 | 188 |
| Operating expenses: | ||||
| Research and development (Includes $2, $11, $2 and $6 from a related party) | 113 | 139 | 235 | 261 |
| General and administrative(Includes $—, $2, $— and $2 from a related party) | 24 | 29 | 53 | 57 |
| Total operating expenses | 137 | 168 | 288 | 318 |
Item 1. Financial Statements
FAQ
- What is Arcus Biosciences's other collaboration — total revenues?
- Arcus Biosciences (RCUS) reported other collaboration — total revenues of $25M in Q2 2026.
- How has Arcus Biosciences's other collaboration — total revenues changed year-over-year?
- Arcus Biosciences's other collaboration — total revenues increased by 212.5% year-over-year, from $8M to $25M.
- What is the long-term trend for Arcus Biosciences's other collaboration — total revenues?
- Over 4 years (2021 to 2025), Arcus Biosciences's other collaboration — total revenues has grown at a -9.1% compound annual growth rate (CAGR), from $38M to $26M.
- What does other collaboration — total revenues mean?
- This metric represents the total revenue recognized from strategic partnerships, licensing agreements, or research collaborations that fall outside of the company's primary or core product revenue streams. It captures income generated through milestone payments, upfront fees, or cost-sharing arrangements associated with the development and commercialization of clinical-stage assets. Monitoring this figure helps investors assess the company's ability to monetize its R&D pipeline through external business development activities.
Ask your AI about Arcus Biosciences's other collaboration — total revenues.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude